ACQUISITION	9 Months Ended
Sep. 30, 2013
Business Combinations [Abstract]
ACQUISITION	ACQUISITION On June 25, 2012 (the “Acquisition Date”), pursuant to the terms of an Amended and Restated Agreement and Plan of Merger (the "Acquisition Agreement"), a wholly-owned subsidiary of the Company merged with and into eBioscience, Inc. (“eBioscience”) with eBioscience surviving as a wholly-owned subsidiary of the Company (the "Acquisition"). eBioscience specializes in the development, manufacturing, marketing and distribution of research tools in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The results of operations of the acquired eBioscience business and the fair values of the assets acquired and liabilities assumed have been included in the accompanying Condensed Consolidated Financial Statements since the Acquisition. During the three and nine months ended September 30, 2013, revenue recognized from eBioscience was $19.9 million and $57.7 million, respectively. For the three and nine months ended September 30, 2013, the Company recorded a net loss from eBiosciences of $2.7 million and $10.3 million, respectively. The Company considered the eBioscience fair value analysis to be final as of December 31, 2012.

ACQUISITION

9 Months Ended

Sep. 30, 2013

On June 25, 2012 (the “Acquisition Date”), pursuant to the terms of an Amended and Restated Agreement and Plan of Merger (the "Acquisition Agreement"), a wholly-owned subsidiary of the Company merged with and into eBioscience, Inc. (“eBioscience”) with eBioscience surviving as a wholly-owned subsidiary of the Company (the "Acquisition"). eBioscience specializes in the development, manufacturing, marketing and distribution of research tools in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses.

The results of operations of the acquired eBioscience business and the fair values of the assets acquired and liabilities assumed have been included in the accompanying Condensed Consolidated Financial Statements since the Acquisition. During the three and nine months ended September 30, 2013, revenue recognized from eBioscience was $19.9 million and $57.7 million, respectively. For the three and nine months ended September 30, 2013, the Company recorded a net loss from eBiosciences of $2.7 million and $10.3 million, respectively. The Company considered the eBioscience fair value analysis to be final as of December 31, 2012.